Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Proteo Biotech AG
Kiel, Germany
- Ownership
- Private
- Development stage
- Other
01
Overview
Completed Phase I trial in 2019 for subcutaneous Elafin in healthy volunteers for PAH; no severe adverse events reported. Planned pivotal trial for esophageal cancer postoperative complications.
- Therapeutic areas
- OncologyCardiovascularImmunologyOther
- Modalities
- Recombinant protein
- Industry
- Biotech
02
Partnerships
ARTES Biotechnology GmbHStanford University
Beyond the preview
Go deeper on Proteo Biotech AG.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Proteo Biotech AG.